Arnold, who holds the E. Gerald Corrigan PhD Endowed Chair in Alzheimer Therapeutics at Massachusetts General Hospital, brings extensive experience in bridging biological research with clinical outcomes. His career includes leadership roles at the University of Pennsylvania’s Memory Center and the oversight of early-stage trials at Mass General Brigham. His work, encompassing over 400 peer-reviewed publications, focuses on the molecular mechanisms of cognitive decline and the application of precision medicine in trial design.
Spinogenix Adds Alzheimer’s Authority Steven E. Arnold to Advisory Board
Spinogenix has appointed Harvard Medical School professor Steven E. Arnold to its scientific advisory board, signaling a strategic shift toward biomarker-driven clinical development. As the company prepares for late-stage trials of its synaptic regenerative therapy, Arnold’s expertise in translational neurology will guide the advancement of the drug candidate tazbentetol.
CEO Stella Sarraf noted that Arnold’s integration of biomarker strategies is essential for the company's upcoming registration-directed studies. Spinogenix is currently developing tazbentetol, a first-in-class therapeutic designed to restore synapses in patients with Alzheimer’s, ALS, and schizophrenia. By leveraging EEG data from Phase 2a studies, the board intends to refine how the company measures synaptic regeneration, potentially setting a new standard for neurodegenerative treatment protocols.
Comments (0)
No comments yet. Be the first!